A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery

NCT07188064 — Not applicable, Recruiting, 100 participants, Sir Mortimer B. Davis - Jewish General Hospital

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Prospective Cohort Study of Somatic-Autonomic Nerve Grafting Technique to Restore Erectile Function in Patients With Persistent Erectile Dysfunction Post Radical Prostatectomy

RegistryNCT07188064, acronym PRP NG PRO M
StatusRecruiting
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment100 (Estimated)
SponsorSir Mortimer B. Davis - Jewish General Hospital (Other); collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre, Western University, Canada, Fox Chase Cancer Center
ConditionsProstate Cancer, Erectile Dysfunction Following Radical Prostatectomy
InterventionsPost radical prostatectomy nerve restoration procedure (PRP-NR) (Procedure)
Datesstart 2026-01-30, primary completion 2028-11-01 (estimated), completion 2028-12-01 (estimated), first posted 2025-09-23, last updated 2026-03-10
Locations1 site in Canada

Related Papers Related Patents Related Grants Related Experts
All trials for Prostate Cancer All trials for Erectile Dysfunction Following Radical Prostatectomy All trials of Post radical prostatectomy nerve restoration procedure (PRP-NR)

-Summary

A single arm prospective pilot trial evaluating the 1-year erectile recovery outcomes and the safety of patients undergoing a somatic to autonomic nerve grafting procedure for restoration of erectile function in patients who have lost erectile function following radical prostatectomy for prostate cancer. During this study a total of 100 patients who have persistent erectile dysfunction for more than 18 months post prostatectomy will undergo a post radical prostatectomy nerve restoration procedure (PRP-NR).

Expand all sections  ·  Collapse all

+Detailed description

The investigators are proposing a single arm prospective pilot study evaluating the safety and the 1-year erectile recovery outcomes of patients undergoing the PRP-NR procedure. A total of 100 patients will undergo the PRP-NR procedure, which is a novel nerve grafting procedure which will utilize a graft of the ilioinguial nerve to perform a bilateral end to side connection between the dorsal penile nerve and the corpora cavernosa with the intent to restore erectile function. Participants will have a baseline evaluation with IIEF-5 and SF-MPQ questionnaires, and then will have re-evaluation with these questionnaires at their standard of care post operative visits at 4 weeks, 3-, 6-, 12-, 18- and 24- months. Post operative safety will be assessed by recording any clinically detected complications during their peri- and post-operative care.

+Arms and interventions

ArmTypeInterventionsDescription
Post radical prostatectomy nerve restoration procedureExperimentalProcedure: Post radical prostatectomy nerve restoration procedure (PRP-NR)A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
  • Post radical prostatectomy nerve restoration procedure (PRP-NR) (Procedure): Somatic to autonomic nerve grafting procedure which uses a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa

+Outcome measures

Primary outcomes

  • International Index of Erectile Function-5 (IIEF-5) [4 weeks post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).
  • International Index of Erectile Function-5 (IIEF-5) [3 months post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [24 months post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [18 months post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [12 months post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [6 months post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [3 months post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Clinical Evolution of Erectile Function (CEEF) [4 weeks post PRP-NR]: A one question visual questionnaire evaluating the erectile function, from 0 (no erection - Worst Possible Outcome) to 10 (sexual intercourse - Best Possible Outcome).
  • Short Form McGill Pain Questionnaire (SF-MPQ) [24 months post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • Short Form McGill Pain Questionnaire (SF-MPQ) [18 months post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • Short Form McGill Pain Questionnaire (SF-MPQ) [12 months post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • Short Form McGill Pain Questionnaire (SF-MPQ) [6 months post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • Short Form McGill Pain Questionnaire (SF-MPQ) [3 months post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • Short Form McGill Pain Questionnaire (SF-MPQ) [4 weeks post PRP-NR]: The SF-MPQ was designed to measure post-surgical pain. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. The sum of the scores gives a range of outcomes; a score of 0 (no pain - Best Possible Outcome) to a score of 45 (Most severe pain - Worst Possible Outcome)
  • International Index of Erectile Function-5 (IIEF-5) [24 months post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).
  • International Index of Erectile Function-5 (IIEF-5) [18 months post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).
  • International Index of Erectile Function-5 (IIEF-5) [12 months post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).
  • International Index of Erectile Function-5 (IIEF-5) [6 months post PRP-NR]: The IIEF-5 is used to determine the prevalence of erectile dysfunction (ED) in a non-selected population using the abridged 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool. Each answer has a score from 1 (very low) to 5 (very high). The sum of all the answers gives a final result of 1-7 (Severe ED - Worst Outcome), 8-11 (Moderate ED), 12-16 (Mild-moderate ED), 17-21 (Mild ED) and 22-25 (No ED - Best Outcome).

Secondary outcomes

  • The secondary outcome is specifically the safety of the operation. This will be measured by adverse events as defined by the Clavian-Dindo classification.The measurement varies from Grade I (Best possible outcome) to Grade V (Worst possible outcome). [Through study completion, an average of 2 years]: Grade I - Deviation from normal p/o course. No pharmacological or surgical treatment, endoscopic or radiological interventions were required. Acceptable therapeutic drugs such as anti-emetics, antipyretics, analgesics, diuretics, electrolytes, physiotherapy. Wound infections, small abscess requiring incision at bedside. Grade II - Normal course altered. Pharmacological management other than in Grade I. Blood transfusions and total parenteral nutrition are also included. Grade III - Complications that require intervention of various degrees. Grade IIIa are complications that require an intervention performed under local anaesthesia. Grade IIIb are interventions that require general or epidural anaesthesia. Grade IV - Complications threatening life of patients (including Central Nervous System complications), requiring Intensive Treatment Unit support. Grade IVa are single organ dysfunction (including dialysis). Grade IVb is multi-organ dysfunction. Grade V - Death of a patient.

+Eligibility

Sex: Male, ages: 18 Years to any

Inclusion Criteria:

* Patients with persistent post prostatectomy erectile dysfunction as defined below:

  1. Severe ED (IIEF score 5-7) and more than 12 months from prostatectomy OR
  2. Moderate ED (IIEF score 8-11) and more than 18 months from prostatectomy
* Patients must have had good pre-prostatectomy erectile function with a baseline IIEF score of ≥17 on self-reported assessment of historic function.

Exclusion Criteria:

* Patients aged < 18 years at diagnosis
* Legally incapable patients
* Patients >5 years from prostatectomy.
* Bilateral open inguinal hernia repair
* Patients with pre-existing significant neurologic disease
* Diabetes with evidence of peripheral nerve involvement and end organ dysfunction
* Coronary artery disease with unstable angina
* Mood disorder (anxiety/depression) with change in medical therapy within last 3 months
* Pre-existing penile base surgery which would prevent grafting technique including suprapubic liposuction, suspensory ligament release
* Pre-existing penile prosthesis
* Current use of androgen deprivation therapy
* Use of medications for chronic nerve pain (gabapentin, amitriptyline, nortriptyline, pregablin)
* Previous untreated penile trauma
* Patients deemed medically unfit for surgery

+Locations (1)

FacilityCityCountryStatus
Jewish General HospitalMontreal, QuebecCanadaRecruiting